Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and ge...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/11/1786 |
| _version_ | 1797508819071270912 |
|---|---|
| author | Sara Salvador-Martín Alejandra Melgarejo-Ortuño Luis A. López-Fernández |
| author_facet | Sara Salvador-Martín Alejandra Melgarejo-Ortuño Luis A. López-Fernández |
| author_sort | Sara Salvador-Martín |
| collection | DOAJ |
| description | The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and genetic parameters are considered predictive of response to biological drugs, although few studies have been carried out in children with IBD. In this review, we present current evidence on biological treatments used in pediatric IBD and the available biomarkers of response. We examine demographics, clinical characteristics, biomarkers (genetic, genomic, and cellular), and microbiota. |
| first_indexed | 2024-03-10T05:09:16Z |
| format | Article |
| id | doaj.art-b275a7c3d7d14dff9e7bd172375fb3fe |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T05:09:16Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-b275a7c3d7d14dff9e7bd172375fb3fe2023-11-23T00:57:36ZengMDPI AGPharmaceutics1999-49232021-10-011311178610.3390/pharmaceutics13111786Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel DiseaseSara Salvador-Martín0Alejandra Melgarejo-Ortuño1Luis A. López-Fernández2Servicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, SpainServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, SpainServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, SpainThe use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and genetic parameters are considered predictive of response to biological drugs, although few studies have been carried out in children with IBD. In this review, we present current evidence on biological treatments used in pediatric IBD and the available biomarkers of response. We examine demographics, clinical characteristics, biomarkers (genetic, genomic, and cellular), and microbiota.https://www.mdpi.com/1999-4923/13/11/1786biomarkerspharmacogenomicspersonalized medicineinflammatory bowel diseaseinfliximabadalimumab |
| spellingShingle | Sara Salvador-Martín Alejandra Melgarejo-Ortuño Luis A. López-Fernández Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease Pharmaceutics biomarkers pharmacogenomics personalized medicine inflammatory bowel disease infliximab adalimumab |
| title | Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease |
| title_full | Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease |
| title_fullStr | Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease |
| title_full_unstemmed | Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease |
| title_short | Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease |
| title_sort | biomarkers for optimization and personalization of anti tnfs in pediatric inflammatory bowel disease |
| topic | biomarkers pharmacogenomics personalized medicine inflammatory bowel disease infliximab adalimumab |
| url | https://www.mdpi.com/1999-4923/13/11/1786 |
| work_keys_str_mv | AT sarasalvadormartin biomarkersforoptimizationandpersonalizationofantitnfsinpediatricinflammatoryboweldisease AT alejandramelgarejoortuno biomarkersforoptimizationandpersonalizationofantitnfsinpediatricinflammatoryboweldisease AT luisalopezfernandez biomarkersforoptimizationandpersonalizationofantitnfsinpediatricinflammatoryboweldisease |